Article
SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine-Resistance in Pancreatic Cancer
2023-09-13
Abstract excerpt
Pancreatic cancer has a poor prognosis with its five-year survival rate lower than that of any other cancer type because it is difficult to detect in the early stages. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance. Therefore, novel therapeutic targets must be identified to overcome gemcitabine-resistance. Here, we found that SLC38A5, a...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- df3daa1b-10d0-5d6b-8174-9280c7a12fa4
- DOI
- 10.20944/preprints202309.0814.v1
